Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
New Research from the Caris Precision Oncology Alliance Finds Prognostic and Predictive Drug-Induced Gene Signatures for Colorectal Cancer Patients
Caris Life Sciences® (Caris), the leading molecular science and technology company actively developing and delivering […]
Caris Life Sciences and HotSpot Therapeutics Announce Collaboration to Advance Precision Medicine Development for Difficult-to-Drug Therapeutic Targets
Caris Life Sciences® (Caris), the leading molecular science and technology company actively developing and delivering innovative […]
Caris Life Sciences Announces Appointment of Rob Clark as Chief Communications Officer
Caris Life Sciences® (Caris), a molecular science company developing and delivering technologies to revolutionize healthcare, announced today […]
Caris Life Sciences Announces Appointment of Lloyd B. Minor to Board of Directors
Caris Life Sciences® (Caris), the leading molecular science and technology company actively developing and delivering innovative […]
Caris Precision Oncology Alliance Announces the Addition of Columbia University Irving Medical Center to Its Collaborative Network of Precision Medicine Experts
Caris Life Sciences® (Caris), the leading molecular science and technology company actively developing and delivering innovative […]
Caris’ Precision Oncology Alliance Welcomes The Georgia Cancer Center at Augusta University
Caris Life Sciences® (Caris), the leading molecular science and technology company actively developing and delivering innovative […]
Caris Precision Oncology Alliance Partners with the National Cancer Institute, Part of the National Institutes of Health, to Expand Collaborative Clinical Research Efforts
Caris Life Sciences® (Caris), a molecular science company developing and delivering technologies to revolutionize healthcare, announced […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more